News
3h
Zacks.com on MSNIGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue EstimatesIGM Biosciences (IGMS) delivered earnings and revenue surprises of -109.76% and 91.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
IGM Financial Inc. ( TSE:IGM ) has announced that it will pay a dividend of CA$0.5625 per share on the 31st of ...
Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...
Sales started to slow in the spring, as market uncertainty began to weigh on investor confidence, says CEO James O’Sullivan ...
After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...
2d
News Medical on MSNSniffing Out the Flu: How a Supercharged Nasal Antibody Shields Against Viral AmbushScientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.
US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...
IGM Financial Inc. reported adjusted net earnings of $237.8 million for the first quarter, up 5.9% from the same quarter of ...
Detailed price information for Igm Financial Inc (IGM-T) from The Globe and Mail including charting and trades.
Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the ...
Thank you for standing by. This is the conference operator. Welcome to the IGM Financial First Quarter 2025 Analyst Call and Webcast. As a reminder, all participants are in a listen-only mode and ...
A new multiplex protein microarray has shown promise in accurately detecting a wide range of tick-borne infections in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results